Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Полное описание

Библиографические подробности
Главные авторы:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Формат:	Journal article
Опубликовано:	BioMed Central 2018

Схожие документы

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
по: Philip Helliwell, и др.
Опубликовано: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
по: Helliwell, P, и др.
Опубликовано: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
по: Nash, P, и др.
Опубликовано: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
по: Nash, P, и др.
Опубликовано: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
по: E. Yu. Loginova, и др.
Опубликовано: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
по: Coates, L, и др.
Опубликовано: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
по: Tucker, L, и др.
Опубликовано: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
по: Miao Chen, и др.
Опубликовано: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
по: Lubrano, E, и др.
Опубликовано: (2019)

Current concepts and unmet needs in psoriatic arthritis
по: Mahmood, F, и др.
Опубликовано: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
по: Nash, P, и др.
Опубликовано: (2018)

Remission in psoriatic arthritis—where are we now?
по: Coates, L, и др.
Опубликовано: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
по: P.S. Helliwell
Опубликовано: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
по: Ennio Lubrano, и др.
Опубликовано: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
по: Coates, LC, и др.
Опубликовано: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
по: Coates, L, и др.
Опубликовано: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
по: Coates, L, и др.
Опубликовано: (2018)

Best-practice indicators in Psoriatic disease care
по: Helliwell, P, и др.
Опубликовано: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
по: Coates, L, и др.
Опубликовано: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
по: Coates, LC, и др.
Опубликовано: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
по: Peter Nash, и др.
Опубликовано: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
по: Mease, P, и др.
Опубликовано: (2018)

Psoriatic arthritis
по: FitzGerald, O, и др.
Опубликовано: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
по: Laura C. Coates, и др.
Опубликовано: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
по: Jiao Wang, и др.
Опубликовано: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
по: Coates, L, и др.
Опубликовано: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
по: Soriano, ER, и др.
Опубликовано: (2023)

Psoriatic Arthritis: A Review
по: Farrouq Mahmood, и др.
Опубликовано: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
по: Helliwell, PS, и др.
Опубликовано: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
по: E. E. Gubar, и др.
Опубликовано: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
по: Laure Gossec, и др.
Опубликовано: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
по: Coates, LC
Опубликовано: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
по: Vivekanantham, A, и др.
Опубликовано: (2024)

Measuring outcomes in psoriatic arthritis
по: Ogdie, A, и др.
Опубликовано: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
по: Vishal R. Tandon, и др.
Опубликовано: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
по: Braun, J, и др.
Опубликовано: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
по: Philip J. Mease, и др.
Опубликовано: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
по: Yazji, SM, и др.
Опубликовано: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
по: Nash, P, и др.
Опубликовано: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
по: Coates, LC, и др.
Опубликовано: (2022)